Rubraca Gets FDA Approval for Prostate Cancer!

PCEC is so happy to announce that the U.S. Food and Drug Administration (FDA) approved rucaparib, a new medication to treat patients with a BRCA mutation for advanced prostate cancer. Medical advancements like these are what continue to inspire and bring hope to everyone in the fight against prostate cancer!  Click below to learn more.

Rubraca gets FDA Approval for Prostate Cancer

If you are interested in learning more about the BRCA mutation and prostate cancer treatment check out BRCABlue.com!

BRCA Blue

 Screen Shot 2020 04 20 at 4.15.58 PM

 

Prostate cancer is a disease that is most successfully treated when it is detected early on.  As the research community explores various methods to detecting the disease, PCEC continues to encourage men to play an active role in their health by looking to those trusted sources of prostate cancer testing – the PSA and DRE.

~Dr. E. David Crawford
Head of the Urologic Oncology Department at the University of Colorado Health Sciences Center
Founder/Chairman of PCEC

Join Our Newsletter

btn amazon